Subclinical atherosclerosis burden in non-diabetic hypertensives treated in primary care center: the IMTABI study

José M Ramírez-Torres1, Antonio López-Téllez1, María J Ariza2

  • 1Centro de Salud Puerta Blanca, Servicio Andaluz de Salud, Málaga, Spain.

BMC Primary Care
|February 9, 2023
PubMed

Insights

Many non-diabetic hypertensive patients have undetected atherosclerosis, increasing their cardiovascular disease risk. Early detection through screening can reclassify patients to very high-risk, prompting necessary treatment adjustments.

Area of Science:

  • Cardiology
  • Primary Care Medicine
  • Diagnostic Imaging

Background:

  • Cardiovascular disease (CVD) risk stratification in primary prevention is challenging.
  • Subclinical atherosclerosis detection in non-diabetic hypertensive patients is crucial for accurate risk assessment.

Purpose of the Study:

  • To identify subclinical atherosclerosis burden in non-diabetic hypertensive patients within a primary care setting.
  • To assess the impact of subclinical atherosclerosis on cardiovascular risk reclassification.

Main Methods:

  • Collected clinical, anthropometric, and analytical data from hypertensive patients without prior vascular disease or diabetes.
  • Assessed cardiovascular risk using the SCORE system.
  • Evaluated subclinical atherosclerosis via carotid ultrasonography (intima-medial thickness [IMT] and plaque) and ankle-brachial index (ABI).

Main Results:

  • 65% of patients exhibited total atherosclerosis burden.
  • 42% of patients were reclassified to the very high-risk category due to subclinical atherosclerosis.
  • Smoking, creatinine levels, and hypertension duration were linked to atherosclerosis burden.

Conclusions:

  • A significant proportion (40%) of non-diabetic hypertensive patients in primary care have subclinical atherosclerosis, necessitating risk reclassification.
  • Lipid-lowering drug undertreatment was evident, with many patients not meeting LDL cholesterol goals per guidelines.
Abstract

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
36
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
26
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
23
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
29
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
31